CYP2C9 allelic variants: Ethnic distribution and functional significance

Advanced Drug Delivery Reviews

Volumn 54, Issue 10, 2002, Pages 1257-1270

  Xie, Hong Guang ^a,b   Prasad, Harish C ^a   Kim, Richard B ^a   Stein, C Michael ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Allelic variants; CYP2C9; Ethnic variability; Genotyping; Meta analysis; Pharmacogenetics; Polymorphism

Indexed keywords

ENZYMES; METABOLISM; SUBSTRATES;

POLYMORPHISMS;

DRUG PRODUCTS;

ACENOCOUMAROL; CELECOXIB; CYTOCHROME P450 2C9; FLUINDOSTATIN; GLIPIZIDE; LOSARTAN; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYTOIN; TOLBUTAMIDE; TORASEMIDE; WARFARIN; CYP2C9 PROTEIN, HUMAN; UNSPECIFIC MONOOXYGENASE;

ALLELE; DRUG METABOLISM; ENZYME ACTIVITY; ETHNIC DIFFERENCE; ETHNOLOGY; GENE ACTIVITY; GENE DOSAGE; GENE FREQUENCY; GENETIC CODE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; RACE DIFFERENCE; REVIEW; STRUCTURE ACTIVITY RELATION; ASIAN; CAUCASIAN; ENZYME SPECIFICITY; GENETICS; NEGRO;

AFRICAN CONTINENTAL ANCESTRY GROUP; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENE FREQUENCY; HUMANS; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); SUBSTRATE SPECIFICITY;

EID: 0037131892     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(02)00076-5     Document Type: Article

References (83)

1. Rendic S., di Carlo F.J. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab. Rev. 29:1997;413-580.
2. Xie H.G., Kim R.B., Wood A.J.J., Stein C.M. Molecular basis of ethnic differences in drug disposition and response. Cho A.K., Blaschke T.F., Insel P.A., Loh H.H., Annual Review of Pharmacology and Toxicology. Vol. 41:2001;815-850 Annual Reviews, Palo Alto, CA.
3. Nelson D.R., Koymans L., Kamataki T., Stegeman J.J., Feyereisen R., Waxman D.J., Waterman M.R., Gotoh O., Coon M.J., Estabrook R.W., Gunsalus I.C., Nebert D.W. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics. 6:1996;1-42.
4. Shimada T., Yamazaki H., Mimura M., Inui Y., Guengerich F.P. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270:1994;414-423.
5. Inoue K., Yamazaki H., Imiya K., Akasaka S., Guengerich F.P., Shimada T. Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4′-hydroxylation activities in livers of Japanese and Caucasian populations. Pharmacogenetics. 7:1997;103-113.
6. Goldstein J.A., de Morais S.M.F. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics. 4:1994;285-299.
7. Miners J.O., Birkett D.J. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br. J. Clin. Pharmacol. 45:1998;525-538.
8. Streetman D.S., Bertino J.S. Jr., Nafziger A.N. Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics. 10:2000;187-216.
9. 24. Genomics. 28:1995;328-332.
10. de Morais S.M.F., Schweiki H., Blaisdell J., Goldstein J.A. Gene structure and upstream regulatory regions of human CYP2C9 and CYP2C18. Biochem. Biophys. Res. Commun. 194:1993;194-201.
11. Romkes M., Faletto M.B., Blaisdell J.A., Raucy J.L., Goldstein J.A. Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily. Biochemistry. 30:1991;3247-3255.
12. Shintani M., Ieiri I., Inoue K., Mamiya K., Ninomiya H., Tashiro N., Higuchi S., Otsubo K. Genetic polymorphisms and functional characterization of the 5′-flanking region of the human CYP2C9 gene: in vitro and in vivo studies. Clin. Pharmacol. Ther. 70:2001;175-182.
13. Xiang S.-H., Parsons H.K., Murray M. Identification of a novel transcriptional silencer in the protein-coding region of the human CYP2C9 gene. Gene. 209:1998;123-129.
14. Ibeanu G.C., Goldstein J.A. Transcriptional regulation of human CYP2C genes: functional comparison of CYP2C9 and CYP2C18 promoter regions. Biochemistry. 34:1995;8028-8036.
15. Ged C., Umbenhauer D.R., Bellew T.M., Bork R.W., Srivastava P.K., Shinriki N., Lloyd R.S., Guengerich F.P. Characterization of cDNAs, mRNAs, and proteins related to human liver microsomal cytochrome P450(s)-mephenytoin 4′-hydroxylase. Biochemistry. 27:1988;6929-6940.
16. Wang S.-L., Huang J.-D., Lai M.-D., Tsai J.-J. Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. Pharmacogenetics. 5:1995;37-42.
17. 359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics. 6:1996;341-349.
18. Margaglione M., Colaizzo D., D'Andrea G., Brancaccio V., Ciampa A., Grandone E., di Minno G. Genetic modulation of oral anticoagulation with warfarin. Thromb. Haemost. 84:2000;775-778.
19. Hiratsuka M., Agatsuma Y., Mizugaki M. Rapid detection of CYP2C9*3 alleles by real-time fluorescence PCR based on SYBR Green. Mol. Genet. Metab. 68:1999;357-362.
20. Gaedigk A., Casley W.L., Tyndale R.F., Sellers E.M., Jurima-Romet M., Leeder J.S. Cytochrome P4502C9 (CYP2C9) allele frequencies in Canadian Native Indian and Inuit populations. Can. J. Physiol. Pharmacol. 79:2001;841-847.
21. Imai J., Ieiri I., Mamiya K., Miyahara S., Furuumi H., Nanba E., Yamane M., Fukumaki Y., Ninomiya H., Tashiro N., Otsubo K., Higuchi S. Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: genetic analysis of the CYP2C9 locus. Pharmacogenetics. 10:2000;85-89.
22. Dickmann L.J., Rettie A.E., Kneller M.B., Kim R.B., Wood A.J.J., Stein C.M., Wilkinson G.R., Schwarz U.I. Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. Mol. Pharmacol. 60:2001;382-387.
23. Xie H.-G., Prasad H., Landau R., Kim R.B., Cai W.-M., Ieiri I., Smiley R.M., Wilkinson G.R., Stein C.M., Wood A.J.J. Frequency of the defective CYP2C9 variant alleles in different ethnic groups [abstract]. Clin. Pharmacol. Ther. 71:2002;P102.
24. Strom A.R., Bradford L.D., Rettie A.E., Leeder J.S., Gaedigk A. Allele frequency of a new CYP2C9 allele (CYP2C9*4) in Caucasians and African-Americans. Drug Metab. Rev. 32:2000;P299.
25. Gotoh O. Substrate recognition sites in cytochrome P-450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. J. Biol. Chem. 267:1992;83-90.
26. Aithal G.P., Day C.P., Leathart J.B.S., Daly A.K. Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis. Pharmacogenetics. 10:2000;511-518.
27. Ieiri I., Tainaka H., Morita T., Hadama A., Mamiya K., Hayashibara M., Ninomiya H., Ohmori S., Kitada M., Tashiro N., Higuchi S., Otsubo K. Catalytic activity of three variants (Ile, Leu, and Thr) at amino acid residue 359 in human CYP2C9 gene and simultaneous detection using single-strand conformation polymorphism analysis. Ther. Drug Monit. 22:2000;237-244.
28. Kidd R.S., Curry T.B., Gallagher S., Edeki T., Blaisdell J., Goldstein J.A. Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. Pharmacogenetics. 11:2001;803-808.
29. Leung A.Y.H., Chow H.C.H., Kwong Y.L., Lie A.K.W., Fung A.T.K., Chow W.H., Yip A.S.B., Liang R. Genetic polymorphism in exon 4 of cytochrome P450 CYP2C9 may be associated with warfarin sensitivity in Chinese patients. Blood. 98:2001;2584-2587.
30. Schwarz U.I., Wilburn B., Choo E.F., Dresser G.K., Kim R.B. Identification of three new CYP2C9 variants. Clin. Pharmacol. Ther. [abstr.]. 69:2001;69.
31. Stubbins M.J., Harries L.W., Smith G., Tarbit M.H., Wolf C.R. Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics. 6:1996;429-439.
32. Nasu K., Kubota T., Ishizaki T. Genetic analysis of CYP2C9 polymorphism in a Japanese population. Pharmacogenetics. 7:1997;405-409.
33. Aynacioglu A.S., Brockmöller J., Bauer S., Sachse C., Güzelbey P., Öngen Z., Nacak M., Roots I. Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. Br. J. Clin. Pharmacol. 48:1999;409-415.
34. Leung A.Y.H., Liang R.H.S. Studies on cytochrome P450 CYP2C9 genetic polymorphism in Chinese patients receiving warfarin [abstract]. Blood. 94:1999;108b.
35. Pirmohamed M., Alfirevic A., Vilar J., Stalford A., Wilkins E.G.L., Sim E., Park B.K. Association analysis of drug metabolizing enzyme gene polymorphisms in HIV-positive patients with co-trimoxazole hypersensitivity. Pharmacogenetics. 10:2000;705-713.
36. Taube J., Halsall D., Baglin T. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood. 96:2000;1816-1819.
37. Yoon Y.-R., Shon J.-H., Kim M.-K., Lim Y.-C., Lee H.-R., Park J.-Y., Cha I.-J., Shin J.-G. Frequency of cytochrome P450 2C9 mutant alleles in a Korean population. Br. J. Clin. Pharmacol. 51:2001;277-280.
38. H.G. Xie, R.B. Kim, Genetic polymorphisms of cytochrome P-450s and drug transporters and infectious disease management, in: D.H. Persing (Ed.), Diagnostic Molecular Microbiology: Principles and Applications, 2nd Edition, American Society for Microbiology, DC, 2002, in press.
39. Yasar Ü., Eliasson E., Dahl M.-L., Johansson I., Ingelman-Sundberg M., Sjöqvist F. Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochem. Biophys. Res. Commun. 254:1999;628-631.
40. Daly A.K., Day C.P., Aithal G.P. CYP2C9 polymorphism and warfarin dose requirements. Br. J. Clin. Pharmacol. 53:2002;408-409.
41. Goldstein J.A. CYP2C9 polymorphisms and CYP2C9*2 genotyping primers. Br. J. Clin. Pharmacol. 53:2002;409-410.
42. Rettie A.E., Wienkers L.C., Gonzalez F.J., Trager W.F., Korzekwa K.R. Impaired S-warfarin metabolism catalyzed by R144C allelic variant of CYP2C9. Pharmacogenetics. 4:1994;39-42.
43. Haining R.L., Hunter A.P., Veronese M.E., Trager W.F., Rettie A.E. Allelic variants of human cytochrome P450 2C9:baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms. Arch. Biochem. Biophys. 333:1996;447-458.
44. Crespi C.L., Miller V.P. The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase. Pharmacogenetics. 7:1997;203-210.
45. 359 variants: enzyme kinetic study with seven substrates. Pharmacogenetics. 10:2000;95-104.
46. Yamazaki H., Inoue K., Chiba K., Ozawa N., Kawai T., Suzuki Y., Goldstein J.A., Guengerich F.P., Shimada T. Comparative studies on the catalytic roles of cytochrome P4502C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes. Biochem. Pharmacol. 56:1998;243-251.
47. Rettie A.E., Haining R.L., Bajpai M., Levy R.H. A common genetic basis for idiosyncratic toxicity of warfarin and phenytoin. Epilepsy Res. 35:1999;253-255.
48. Takahashi H., Kashima T., Nomoto S. Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes. Pharmacogenetics. 8:1998;365-373.
49. Scordo M.G., Spina E., Dahl M.L., Pengo V., Padrini R. Effect of CYP2C9 polymorphism on warfarin maintenance dose and plasma S:R ratio [abstract]. Br. J. Clin. Pharmacol. 51:2001;375P.
50. Steward D.J., Haining R.L., Henne K.R., Davis G., Rushmore T.H., Trager W.F., Rettie A.E. Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Pharmacogenetics. 7:1997;361-367.
51. Ogg M.S., Brennan P., Meade T., Humphries S.E. CYP2C9*3 allelic variant and bleeding complications. Lancet. 354:1999;1124.
52. Tabrizi A.R., McGrath S.D., Blinder M.A., Buchman T.G., Zehnbauer B.A., Freeman B.D. Extreme warfarin sensitivity in siblings associated with multiple cytochrome P450 polymorphisms. Am. J. Hematol. 67:2001;144-146.
53. Thijssen H.H.W., Verkooijen I.W.C., Frank H.L.L. The possession of the CYP2C9*3 allele is associated with low dose requirement of acenocoumarol. Pharmacogenetics. 10:2000;757-760.
54. Verstuyft C., Morin S., Robert A., Loriot M.A., Beaune P., Jaillon P., Becquemont L. Early acenocoumarol overanticoagulation among cytochrome P450 2C9 poor metabolizers. Pharmacogenetics. 11:2001;735-737.
55. McCrea J.B., Cribb A., Rushmore T., Osborne B., Gillen L., Lo M.-W., Waldman S., Bjornsson T., Spielberg S., Goldberg M.R. Phenotypic and genotypic investigations of a healthy volunteer deficient in the conversion of losartan to its active metabolite E-3174. Clin. Pharmacol. Ther. 65:1999;348-352.
56. Yasar Ü., Forslund-Bergengren C., Tybring G., Dorado P., Llerena A., Sjöqvist F., Eliasson E., Dahl M.L. Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. Clin. Pharmacol. Ther. 71:2002;89-98.
57. Kidd R.S., Straughn A.B., Meyer M.C., Blaisdell J., Goldstein J.A., Dalton J.T. Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele. Pharmacogenetics. 9:1999;71-80.
58. Higashi M.K., Veenstra D.L., Kondo L.M., Wittkowsky A.K., Srinouanprachanh S.L., Farin F.M., Rettie A.E. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. J. Am. Med. Assoc. 287:2002;1690-1698.
59. Aithal G.P., Day C.P., Kesteven P.J.L., Daly A.K. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet. 353:1999;717-719.
60. Takahashi H., Echizen H. Pharmacogenetics of warfarin elimination and its clinical implications. Clin. Pharmacokinet. 40:2001;587-603.
61. Odani A., Hashimoto Y., Otsuki Y., Uwai Y., Hattori H., Furusho K., Inui K. Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy. Clin. Pharmacol. Ther. 62:1997;287-292.
62. Kimura M., Ieiri I., Mamiya K., Urae A., Higuchi S. Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population. Ther. Drug Monit. 20:1998;243-247.
63. Mamiya K., Ieiri I., Shimamoto J., Yukawa E., Imai J., Ninomiya H., Yamada H., Otsubo K., Higuchi S., Tashiro N. The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics. Epilepsia. 39:1998;1317-1323.
64. London S.J., Daly A.K., Leathart J.B., Navidi W.C., Idle J.R. Lung cancer risk in relation to the CYP2C9*1/CYP2C9*2 genetic polymorphism among African-Americans and Caucasians in Los Angeles County, California. Pharmacogenetics. 6:1996;527-533.
65. Scordo M.G., Aklillu E., Yasar U., Dahl M.-L., Spina E., Ingelman-Sundberg M. Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. Br. J. Clin. Pharmacol. 52:2001;447-450.
66. London S.J., Sullivan-Klose T., Daly A.K., Idle J.R. Lung cancer risk in relation to the CYP2C9 genetic polymorphism among Caucasians in Los Angeles County. Pharmacogenetics. 7:1997;401-404.
67. Nafziger A.N., Kim J.S., Gaedigk A., Leeder J.S., Kearns G.L., Bertino J.S. Jr. CYP2C9 mutant allele frequencies in a rural US Caucasian population [abstract]. Clin. Pharmacol. Ther. 67:2000;120.
68. Furuya H., Fernandez-Salguero P., Gregory W., Taber H., Steward A., Gonzalez F.J., Idle J.R. Genetic polymorphism of CYP2C9 and its effects on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. Pharmacogenetics. 5:1995;389-392.
69. van der Weide J., Steijns L.S.W., van Weelden M.J.M., de Haan K. The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement. Pharmacogenetics. 11:2001;287-291.
70. Morin S., Loriot M.A., Poirier J.M., Tenneze L., Beaune P.H., Funck-Brentano C., Jaillon P., Becquemont L. Is diclofenac a valuable CYP2C9 probe in humans? Eur. J. Clin. Pharmacol. 56:2001;793-797.
71. Brockmöller J., Rost K.L., Gross D., Schenkel A., Roots I. Phenotyping of CYP2C19 with enantiospecific HPLC-quantification of (R)- and (S)-mephenytoin and comparison with the intron 4/exon 5 G→A-splice site mutation. Pharmacogenetics. 5:1995;80-88.
72. Ackermann E., Cascorbi I., Sachse C., Brockmöller J., Mrozikiewicz P.M., Roots I. Frequencies and the allelic linkage of CYP2C9 mutations in a German population, and the detection of a C/T mutation in intron 2 [abstract]. Eur. J. Clin. Pharmacol. 52:1997;A71.
73. Ozawa S., Shoket B., McDaniel L.P., Tang Y.M., Ambrosone C.B., Kostic S., Vincze I., Kadlubar F.F. Analyses of bronchial bulky DNA adult levels and CYP2C9, GSTP1 and NQO1 genotypes in a Hungarian study populations with pulmonary diseases. Carcinogenesis. 20:1999;991-995.
74. García-Martín E., Martínez C., Ladero J.M., Gamito F.J.G., Agúndez J.A.G. High frequency of mutations related to impaired CYP2C9 metabolism in a Caucasian population. Eur. J. Clin. Pharmacol. 57:2001;47-49.
75. Weibert R.T., Palinkas L.A. Differences in warfarin dose requirements between Asian and Caucasian patients [abstract]. Clin. Pharmacol. Ther. 49:1991;151.
76. Yu H.C.M., Chan T.Y.K., Critchley J.A.J.H., Woo K.S. Factors determining the maintenance dose of warfarin in Chinese patients. Q. J. Med. 89:1996;127-135.
77. Kaminsky L.S., Zhang Z.-Y. Human P450 metabolism of warfarin. Pharmacol. Ther. 73:1997;67-74.
78. Freeman B.D., Zehnbauer B.A., McGrath S., Borecki I., Buchman T.G. Cytochrome P450 polymorphisms are associated with reduced warfarin dose. Surgery. 128:2000;281-285.
79. Takahashi H., Kashima T., Nomizo Y., Muramoto N., Shimizu T., Nasu K., Kubota T., Kimura S., Echizen H. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes. Clin. Pharmacol. Ther. 63:1998;519-528.
80. H. Takahashi, G.R. Wilkinson, Y. Caraco, M. Muszkat, R.B. Kim, T. Kashima, S. Kimura, H. Echizen, Population differences in (S)-warfarin metabolism between CYP2C9 genotype-matched Caucasians and Japanese, Clin. Pharmacol. Ther., in press.
81. Shorr R.I., Ray W.A., Daugherty J.R., Griffin M.R. Individual sulfonylureas and serious hypoglycemia in older people. J. Am. Geriatr. Soc. 44:1996;751-755.
82. White R.H., Beyth R.J., Zhou H., Romano P.S. Major bleeding after hospitalization for deep-venous thrombosis. Am. J. Med. 107:1999;414-424.
83. Blann A., Hewitt J., Siddiqui F., Bareford D. Racial background is a determinant of average warfarin dose required to maintain the INR between 2.0 and 3.0. Br. J. Haematol. 107:1999;207-209.